Creative Planning Sells 55,044 Shares of Sanofi $SNY

Creative Planning decreased its position in Sanofi (NASDAQ:SNY) by 20.1% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 219,439 shares of the company’s stock after selling 55,044 shares during the quarter. Creative Planning’s holdings in Sanofi were worth $10,601,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of the company. Brighton Jones LLC increased its holdings in Sanofi by 52.6% during the 4th quarter. Brighton Jones LLC now owns 5,420 shares of the company’s stock valued at $261,000 after purchasing an additional 1,869 shares during the period. Gallacher Capital Management LLC grew its position in shares of Sanofi by 12.9% in the 1st quarter. Gallacher Capital Management LLC now owns 6,325 shares of the company’s stock worth $351,000 after buying an additional 721 shares during the last quarter. Allianz Asset Management GmbH grew its position in shares of Sanofi by 33.8% in the 1st quarter. Allianz Asset Management GmbH now owns 42,000 shares of the company’s stock worth $2,329,000 after buying an additional 10,600 shares during the last quarter. HighPoint Advisor Group LLC increased its stake in shares of Sanofi by 6.3% during the first quarter. HighPoint Advisor Group LLC now owns 9,555 shares of the company’s stock valued at $513,000 after buying an additional 570 shares during the period. Finally, SYM FINANCIAL Corp bought a new position in shares of Sanofi during the first quarter valued at approximately $242,000. 14.03% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

SNY has been the topic of several recent analyst reports. Morgan Stanley upgraded shares of Sanofi from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $56.00 to $58.00 in a report on Monday, September 8th. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a “hold” rating to a “buy” rating in a research note on Tuesday, September 2nd. Wall Street Zen upgraded shares of Sanofi from a “hold” rating to a “buy” rating in a research report on Saturday, August 2nd. JPMorgan Chase & Co. upgraded shares of Sanofi from a “neutral” rating to an “overweight” rating in a report on Friday, August 8th. Finally, Jefferies Financial Group reaffirmed a “buy” rating on shares of Sanofi in a research report on Monday, October 27th. Two investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $62.67.

Sanofi Price Performance

SNY opened at $50.66 on Wednesday. The company has a current ratio of 1.06, a quick ratio of 0.94 and a debt-to-equity ratio of 0.16. The company has a market cap of $124.40 billion, a price-to-earnings ratio of 11.86, a price-to-earnings-growth ratio of 1.38 and a beta of 0.49. The stock has a fifty day simple moving average of $49.16 and a two-hundred day simple moving average of $49.35. Sanofi has a 12-month low of $44.62 and a 12-month high of $60.12.

Sanofi (NASDAQ:SNY) last announced its earnings results on Friday, October 24th. The company reported $1.70 EPS for the quarter, beating analysts’ consensus estimates of $1.60 by $0.10. The firm had revenue of $14.53 billion for the quarter, compared to analysts’ expectations of $12.62 billion. Sanofi had a net margin of 21.96% and a return on equity of 12.70%. The company’s quarterly revenue was down 7.5% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.25 EPS. Research analysts predict that Sanofi will post 4.36 earnings per share for the current fiscal year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.